The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer

Cermik, Tevfik Fikret; Sanli, Yasemin; Yegen, Gulcin; Kaytan Saglam, Esra; alçın, göksel

doi:10.4274/mirt.galenos.2020.40316

The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer

Göksel ALÇIN, (Sağlık ve Bilim Üniversitesi, İstanbul Eğitim ve Araştırma Hastanesi, Nükleer Tıp Kliniği, İstanbul, Türkiye)

Yasemin ŞANLI, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Nükleer Tıp Anabilim Dalı, İstanbul, Türkiye)

Gülçin YEĞEN, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Patoloji Anabilim Dalı, İstanbul, Türkiye)

Esra KAYTAN SAĞLAM, (İstanbul Üniversitesi, İstanbul Tıp Fakültesi, Radyasyon Onkolojisi Anabilim Dalı, İstanbul, Türkiye)

Tevfik Fikret ÇERMİK (Sağlık ve Bilim Üniversitesi, İstanbul Eğitim ve Araştırma Hastanesi, Nükleer Tıp Kliniği, İstanbul, Türkiye)

Molecular Imaging and Radionuclide Therapy

0 0

Yıl: 2020 Cilt: 29 Sayı: 2 Sayfa Aralığı: 65 - 71 Metin Dili: İngilizce DOI: 10.4274/mirt.galenos.2020.40316 İndeks Tarihi: 05-10-2020

The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer

Öz:

Objectives: The aim of this study was to evaluate the impact of maximum standard uptake value (SUVmax) of the primary tumor and locoregionalmetastatic lymph node in predicting survival in patients with the preoperative rectal adenocarcinoma.Methods: One hundred and fifteen patients [mean age ± standard deviation (SD): 58.7±11.4 years] with biopsy-proven rectal adenocarcinomaunderwent 18F-fluorodeoxyglucose (FDG) positron emission tomography/computed tomography (PET/CT) imaging for the staging were includedin this study. All patients were followed-up for a minimum of 12 months (mean ± SD: 29.7±13.5 months). Tumor-node-metastasis 2017 clinicalstaging, SUVmax of the primary rectal tumor and locoregional lymph nodes on the PET/CT studies were evaluated.Results: All patients had increased FDG activity of the primary tumor. The mean ± SD SUVmax of the primary tumor and locoregional metastaticlymph node were 21.0±9.1 and 4.6±2.8, respectively. Primary tumor SUVmax did not have an effect on predicting survival (p=0.525) howeverlocoregional metastatic lymph node SUVmax had an effect (p<0.05) on predicting survival. Clinical stage of the disease was a factor predictingsurvival (p<0.001).Conclusion: 18F-FDG PET/CT is an effective imaging modality for detecting primary tumors and metastases in rectal adenocarcinoma and clinicalstage assessment with PET/CT had an effect on predicting survival. Furthermore, in our study locoregional lymph node SUVmax was defined as afactor in predicting survival.

Anahtar Kelime:

Rektal Kanserli Hastalarda Primer Tümör ve Lokorejyonel Metastatik Lenf Nodu SUVmaks’ın Sağkalım Üzerine Belirleyici Etkisi

Öz:

Amaç: Çalışmamızın amacı preoperatif rektum adenokanserli olan hastalarda sağkalımı öngörmede primer tümör ve lokorejyonel metastatik lenf nodu maksimum standart alım değeri (SUVmaks) değerinin etkinliğini değerlendirmektir. Yöntem: Bu çalışmaya, biyopsiyle kanıtlanmış rektal adenokarsinoma ile evreleme amaçlı 18F-florodeoksiglikoz (FDG) pozitron emisyon tomografi/ bilgisayarlı tomografi (PET/BT) görüntüleme yapılan 115 hasta [ortalama yaş ± standart sapma (SS): 58,7±11,4 yıl] dahil edildi. Tüm hastalar en az 12 ay (ortalama ± SS: 29,7±13,5 ay) takip edildi. Tümör-nodül-metastaz 2017 klinik evreleme, primer rektal tümör SUVmaks ve lokorejyonel lenf nodu SUVmaksdeğerlendirildi. Bulgular: Tüm hastalarda primer tümöre ait artmış FDG tutulumu saptandı. Primer tümör ve lokorejyonel metastatik lenf nodu ortalama SUVmaks’ları sırasıyla 21,0±9,1 ve 4,6±2,8 idi. Primer tümör SUVmaks’ın sağkalımı öngörmede bir etkisi saptanmamış olup (p=0,525) lokorejyonel metastatik lenf nodu SUVmaks’ın sağkalımı öngörmede etkisi saptandı (p<0,05). Hastalığın klinik evresi sağkalımı öngören bir faktördü (p<0,001). Sonuç: 18F-FDG PET/BT rektum kanserinde primer tümör ve metastazlarının saptanmasında etkili bir görüntüleme yöntemi olup lokorejyonel lenf nodu SUVmaks değerlerinin prognostik değerinin bulunduğu ve rektum kanserinin tedavi öncesi preoperatif evrelemede hastaların tedavi yönetimine önemli katkılar sağlayacağı düşünülmüştür.

Anahtar Kelime:

Belge Türü: Makale Makale Türü: Araştırma Makalesi Erişim Türü: Erişime Açık

1. Nishihara R, Ogino S, Chan AT. Colorectal-cancer incidence and mortality after screening. N Engl J Med 2013;369:2355.
2. Ferlay J, Colombet M, Soerjomataram I, Dyba T, Randi G, Bettio M, Gavin A, Visser O, Bray F. Cancer incidence and mortality patterns in Europe: Estimates for 40 countries and 25 major cancers in 2018. Eur J Cancer 2018;103:356-387.
3. Hong TS, Ryan DP. Total Neoadjuvant Therapy for Locally Advanced Rectal Cancer-The New Standard of Care? JAMA Oncol 2018;4:e180070.
4. Ozis SE, Soydal C, Akyol C, Can N, Kucuk ON, Yagcı C, Erkek AB, Kuzu MA. The role of 18 F-fluorodeoxyglucose positron emission tomography/ computed tomography in the primary staging of rectal cancer. World J Surg Oncol 2014;12:26.
5. Huang J, Huang L, Zhou J, Duan Y, Zhang Z, Wang X, Huang P, Tan S, Hu P, Wang J, Huang M. Elevated tumor-to-liver uptake ratio (TLR) from 18F-FDG-PET/CT predicts poor prognosis in stage IIA colorectal cancer following curative resection. Eur J Nucl Med Mol Imaging 2017;44:1958- 1968.
6. Nakajo M, Kajiya Y, Tani A, Jinguji M, Nakajo M, Kitazono M, Yoshiura T. A pilot study for texture analysis of 18F-FDG and 18F-FLT-PET/CT to predict tumor recurrence of patients with colorectal cancer who received surgery. Eur J Nucl Med Mol Imaging 2017;44:2158-2168.
7. Deantonio L, Caroli A, Puta E, Ferrante D, Apicella F, Turri L, Sacchetti G, Brambilla M, Krengli M. Does baseline [18F] FDG-PET/CT correlate with tumor staging, response after neoadjuvant chemoradiotherapy, and prognosis in patients with rectal cancer? Radiat Oncol 2018;13:211.
8. Weiser MR. AJCC 8th Edition: Colorectal Cancer. Ann Surg Oncol 2018;25:1454-1455.
9. Engelen SM, Beets-Tan RG, Lahaye MJ, Kessels AG, Beets GL. Location of involved mesorectal and extramesorectal lymph nodes in patients with primary rectal cancer: preoperative assessment with MR imaging. Eur J Surg Oncol 2008;34:776-781.
10. National Institute for Health and Clinical Excellence. Improving outcomes in colorectal cancer. Manual update. London: National Institute for Health and Clinical Excellence; 2004.
11. Tagliabue L. The emerging role of FDG PET/CT in rectal cancer management: is it time to use the technique for early prognostication? Eur J Nucl Med Mol Imaging 2013;40:652-656.
12. Kijima S, Sasaki T, Nagata K, Utano K, Lefor AT, Sugimoto H. Preoperative evaluation of colorectal cancer using CT colonography, MRI, and PET/CT. World J Gastroenterol 2014;20:16964-16975.
13. Sasaki R, Komaki R, Macapinlac H, Erasmus J, Allen P, Forster K, Putnam JB, Herbst RS, Moran CA, Podoloff DA, Roth JA, Cox JD. [18F] fluorodeoxyglucose uptake by positron emission tomography predicts outcome of non-small-cell lung cancer. J Clin Oncol 2005;23:1136-1143.
14. Pan L, Gu P, Huang G, Xue H, Wu S. Prognostic significance of SUV on PET/CT in patients with esophageal cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2009;21:1008-1015.
15. Riedl CC, Akhurst T, Larson S, Stanziale SF, Tuorto S, Bhargava A, Hricak H, Klimstra D, Fong Y. 18F-FDG PET scanning correlates with tissue markers of poor prognosis and predicts mortality for patients after liver resection for colorectal metastases. J Nucl Med 2007;48:771-775.
16. Lee JE, Kim SW, Kim JS, Choi KY, Kang WK, Oh ST, Yoo IeR, Kim SH. Prognostic value of 18-F-fluorodeoxyglucose positron-emission tomography-computed tomography in resectable colorectal cancer. World J Gastroenterol 2012;18:5072-5077.
17. Oku S, Nakagawa K, Momose T, Kumakura Y, Abe A, Watanabe T, Ohtomo K. FDG-PET after radiotherapy is a good prognostic indicator of rectal cancer. Ann Nucl Med 2002;16:409-416.
18. Bang JI, Ha S, Kang SB, Lee KW, Lee HS, Kim JS, Oh HK, Lee HY, Kim SE. Prediction of neoadjuvant radiation chemotherapy response and survival using pretreatment [(18)F] FDG PET/CT scans in locally advanced rectal cancer. Eur J Nucl Med Mol Imaging 2016;43:422-431.
19. Ogawa S, Itabashi M, Kondo C, Momose M, Sakai S, Kameoka S. Prognostic value of total lesion glycolysis measured by 18F-FDG-PET/CT in patients with colorectal cancer. Anticancer Res. 2015;35:3495-3500.
20. Dehdashti F, Grigsby PW, Myerson RJ, Nalbantoglu I, Ma C, Siegel BA. Positron emission tomography with [(18)F]-3’-deoxy-3’fluorothymidine (FLT) as a predictor of outcome in patients with locally advanced resectable rectal cancer: a pilot study. Mol Imaging Biol 2013;15:106- 113.
21. Cerny M, Dunet V, Prior JO, Hahnloser D, Wagner AD, Meuli RA, Schmidt S. Initial Staging of Locally Advanced Rectal Cancer and Regional Lymph Nodes: Comparison of Diffusion-Weighted MRI With 18F-FDG-PET/CT. Clin Nucl Med 2016;41:289-295.
22. Zhou L, Wang JZ, Wang JT, Wu YJ, Chen H, Wang WB, Cao F, Cheng GX. Correlation analysis of MR/CT on colorectal cancer lymph node metastasis characteristics and prognosis. Eur Rev Med Pharmacol Sci 2017;21:1219-1225.
23. Glynne-Jones R, Wyrwicz L, Tiret E, Brown G, Rödel C, Cervantes A, Arnold D; ESMO Guidelines Committee. Rectal cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol 2017;28(Suppl 4):22-40.
24. Bae SU, Won KS, Song BI, Jeong WK, Baek SK, Kim HW. Accuracy of F-18 FDG PET/CT with optimal cut-offs of maximum standardized uptake value according to size for diagnosis of regional lymph node metastasis in patients with rectal cancer. Cancer Imaging 2018;18:32.
25. Chen R, Wang Y, Zhou X, Huang G, Liu J. Preoperative PET/CT 18F-FDG Standardized Uptake by Lymph Nodes as a Significant Prognostic Factor in Patients with Colorectal Cancer. Contrast Media Mol Imaging 2018;2018:5802109.
26. Leccisotti L, Gambacorta MA, de Waure C, Stefanelli A, Barbaro B, Vecchio FM, Coco C, Persiani R, Crucitti A, Tortorelli AP, Giordano A, Valentini V. The predictive value of 18F- FDG PET/CT for assessing pathological response and survival in locally advanced rectal cancer after neoadjuvant radiochemotherapy. Eur J Nucl Med Mol Imaging 2015;42:657-666.
27. Alongi F, Fersino S, Mazzola R, Fiorentino A, Giaj-Levra N, Ricchetti F, Ruggieri R, Di Paola G, Cirillo M, Gori S, Salgarello M, Zamboni G, Ruffo G. Radiation dose intensification in preoperative chemo-radiotherapy for locally advanced rectal cancer. Clin Transl Oncol 2017;19:189-196.
28. Rahmim A, Qi J, Sossi V. Resolution modeling in PET imaging: theory, practice, benefits, and pitfalls. Med Phys 2013;40:064301.
29. Chen SW, Chiang HC, Chen WT, Hsieh TC, Yen KY, Chiang SF, Kao CH. Correlation between PET/CT parameters and KRAS expression in colorectal cancer. Clin Nucl Med 2014;39:685-689.
30. Baldus SE, Schaefer KL, Engers R, Hartleb D, Stoecklein NH, Gabbert HE. Prevalence and heterogeneity of KRAS, BRAF, and PIK3CA mutations in primary colorectal adenocarcinomas and their corresponding metastases. Clin Cancer Res 2010;16:790-799.
31. Kawada K, Nakamoto Y, Kawada M, Hida K, Matsumoto T, Murakami T, Hasegawa S, Togashi K, Sakai Y. Relationship between 18Ffluorodeoxyglucose accumulation and KRAS/BRAF mutations in colorectal cancer. Clin Cancer Res 2012;18:1696-1703.

APA	alçın g, Sanli Y, Yegen G, Kaytan Saglam E, Cermik T (2020). The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer. , 65 - 71. 10.4274/mirt.galenos.2020.40316
Chicago	alçın göksel,Sanli Yasemin,Yegen Gulcin,Kaytan Saglam Esra,Cermik Tevfik Fikret The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer. (2020): 65 - 71. 10.4274/mirt.galenos.2020.40316
MLA	alçın göksel,Sanli Yasemin,Yegen Gulcin,Kaytan Saglam Esra,Cermik Tevfik Fikret The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer. , 2020, ss.65 - 71. 10.4274/mirt.galenos.2020.40316
AMA	alçın g,Sanli Y,Yegen G,Kaytan Saglam E,Cermik T The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer. . 2020; 65 - 71. 10.4274/mirt.galenos.2020.40316
Vancouver	alçın g,Sanli Y,Yegen G,Kaytan Saglam E,Cermik T The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer. . 2020; 65 - 71. 10.4274/mirt.galenos.2020.40316
IEEE	alçın g,Sanli Y,Yegen G,Kaytan Saglam E,Cermik T "The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer." , ss.65 - 71, 2020. 10.4274/mirt.galenos.2020.40316
ISNAD	alçın, göksel vd. "The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer". (2020), 65-71. https://doi.org/10.4274/mirt.galenos.2020.40316

APA	alçın g, Sanli Y, Yegen G, Kaytan Saglam E, Cermik T (2020). The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer. Molecular Imaging and Radionuclide Therapy, 29(2), 65 - 71. 10.4274/mirt.galenos.2020.40316
Chicago	alçın göksel,Sanli Yasemin,Yegen Gulcin,Kaytan Saglam Esra,Cermik Tevfik Fikret The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer. Molecular Imaging and Radionuclide Therapy 29, no.2 (2020): 65 - 71. 10.4274/mirt.galenos.2020.40316
MLA	alçın göksel,Sanli Yasemin,Yegen Gulcin,Kaytan Saglam Esra,Cermik Tevfik Fikret The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer. Molecular Imaging and Radionuclide Therapy, vol.29, no.2, 2020, ss.65 - 71. 10.4274/mirt.galenos.2020.40316
AMA	alçın g,Sanli Y,Yegen G,Kaytan Saglam E,Cermik T The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer. Molecular Imaging and Radionuclide Therapy. 2020; 29(2): 65 - 71. 10.4274/mirt.galenos.2020.40316
Vancouver	alçın g,Sanli Y,Yegen G,Kaytan Saglam E,Cermik T The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer. Molecular Imaging and Radionuclide Therapy. 2020; 29(2): 65 - 71. 10.4274/mirt.galenos.2020.40316
IEEE	alçın g,Sanli Y,Yegen G,Kaytan Saglam E,Cermik T "The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer." Molecular Imaging and Radionuclide Therapy, 29, ss.65 - 71, 2020. 10.4274/mirt.galenos.2020.40316
ISNAD	alçın, göksel vd. "The Impact of Primary Tumor and Locoregional Metastatic Lymph Node SUVmax on Predicting Survival in Patients with Rectal Cancer". Molecular Imaging and Radionuclide Therapy 29/2 (2020), 65-71. https://doi.org/10.4274/mirt.galenos.2020.40316